Xellia Pharmaceuticals Overview
- Founded
-
1903

- Status
-
Private
- Employees
-
1,278

- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
2
- Investments
-
5
Xellia Pharmaceuticals General Information
Description
Developer of active pharmaceutical ingredients designed for treatments against serious and life-threatening infections. The company's anti-infection treatments are genetically prepared that combat serious bacterial and antibiotic-resistant infections as well as certain fungal diseases enabling its clients with improved formulations, drug-device combinations, and in the long term, new anti-infection compounds.
Contact Information
Website
www.xellia.com
Formerly Known As
Axellia Pharmaceuticals, Apothekernes Laboratorium
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
- Dalslandsgade 11
- 2300 Copenhagen
- Denmark
+45 32 00 00 00
Xellia Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Xellia Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of active pharmaceutical ingredients designed for treatments against serious and life-threatening infections.
Pharmaceuticals
Copenhagen, Denmark
1,278
As of 2021
0000
0000-00-00
000000000000
Xellia Pharmaceuticals Competitors (13)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Entasis Therapeutics | Formerly VC-backed | Waltham, MA | 00 | 00000 | 000000&0 | 00000 |
00 000000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000&0 | 00000 |
0000000 000000 | Venture Capital-Backed | Barcelona, Spain | 00 | 0000 | 000000000000 | 0000 |
000 00000000(00000 | Corporation | Cambridge, MA | 000 | 000.00 | 00000000 | 000.00 |
00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 0000000000. |
Xellia Pharmaceuticals Patents
Xellia Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3136500-A1 | Daptomycin aqueous formulations | Pending | 10-May-2019 | 000000000 | |
EP-3620462-A1 | Process for the preparation of caspofungin | Withdrawn | 04-Sep-2018 | 00000000 | 00 |
AU-2018322769-A1 | Daptomycin formulations | Granted | 31-Aug-2017 | 00000000 | |
EP-3675815-A1 | Daptomycin formulations | Pending | 31-Aug-2017 | 000000000 | |
AU-2018322769-B2 | Daptomycin formulations | Active | 31-Aug-2017 | A61K9/19 | 0 |
Xellia Pharmaceuticals Executive Team (11)
Xellia Pharmaceuticals Board Members (9)
Name | Representing | Role | Since |
---|---|---|---|
0000000 0000000 00.0 | Self | Board Member | 000 0000 |
0000000 0000000 | Self | Board Member | 000 0000 |
00000 0000 | Self | Board Member | 000 0000 |
000000 000000 | Novo Holdings | Board Member | 000 0000 |
00000 000000 | Self | Board Member | 000 0000 |
Xellia Pharmaceuticals Signals
Xellia Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Xellia Pharmaceuticals Investments (5)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000 00000 000 | 25-Nov-2015 | 0000000000 | Pharmaceuticals | ||
0000000000000 | 25-Nov-2015 | 0000000000 | Buildings and Property | 0000-0000 | |
000000 000000 | 07-Jul-2014 | 0000000000 | Buildings and Property | 0000-0000 | |
0000000 00000 | 13-May-2010 | 0000000000 | Distributors (Healthcare) | 0000-0000 | |
Pharmaero | 01-Jan-2009 | Joint Venture | Therapeutic Devices | 000000000 |
Xellia Pharmaceuticals Exits (1)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
000000 00000000000 | 07-Jul-2014 | 0000000000 | Completed |
|